Edition:
United Kingdom

People: Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

6.18USD
20 Aug 2019
Change (% chg)

-- (--)
Prev Close
$6.18
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
97,975
52-wk High
$23.33
52-wk Low
$4.21

Patni, Rajiv 

Dr. Rajiv Patni, M.D.. is Chief Medical Officer of the Company. Prior to joining Adamas, Dr. Patni served as Chief Development Officer at Ocera Therapeutics, a biopharmaceutical company, from September 2014 to May 2015, where he was responsible for the management and direction of all drug development activities. From 2007 to August 2014, Dr. Patni served as SVP Chief Medical Officer at Actelion US Pharmaceuticals, a biopharmaceutical company, where he was responsible for overseeing medical and regulatory activities in the United States. Dr. Patni brings over 15 years of global drug development experience and has held senior management roles including as Executive Director/VP, Product Lifecycle Team Leader, Therapeutic Area Head, at Roche Pharmaceuticals, and Senior Medical Director, Development Team Leader, at Novartis and Pfizer Pharmaceuticals. Dr. Patni earned a B.S. from the City University of New York Sophie Davis School of Biomedical Education (accelerated BS/MD Program) and an M.D. from the Mount Sinai School of Medicine.

Basic Compensation

Total Annual Compensation, USD 624,600
Restricted Stock Award, USD 234,148
Long-Term Incentive Plans, USD --
All Other, USD 893,336
Fiscal Year Total, USD 1,752,080

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --